Navigation Links
F-star Expands Management Team

CAMBRIDGE, England, November 2, 2015 /PRNewswire/ --

Appoints Dr Neil Brewis as Chief Scientific Officer  

F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, today announced the appointment of Dr Neil Brewis as Chief Scientific Officer.

Dr Brewis joins F-star from GlaxoSmithKline (GSK) where as Vice President, Head of Biopharmaceutical Research he led a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and protein therapeutics from target validation into early clinical development. This involved leading teams focused on pipeline discovery, platform innovation, translational medicine, clinical immunology, manufacturing process research, and cell line development.

Dr Brewis has 20 years' experience in drug discovery and development and prior to joining GSK, he played a key leadership role, as Head of Research, in the success of building Domantis until the company was acquired by GSK in 2007. He has a PhD in Biochemistry from Dundee University and was awarded an Honorary Doctor of Science from Hertfordshire University in 2014.

Commenting on the appointment, John Haurum, Chief Executive Officer of F-star, said: "We are very pleased to welcome Neil to our team. His significant track record and expertise in applying antibody technologies to discover and develop clinical products will further enable us to move our portfolio of immuno-oncology compounds into the clinic. This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in immuno-oncology. It also demonstrates the unmatched attraction of Cambridge as the foremost biotech cluster in Europe, serving as a key hub for biopharmaceutical companies and academic excellence within antibody drug discovery and development."

Dr Neil Brewis, newly appointed Chief Scientific Officer of F-star, added: "F-star is an emerging world leader in bispecific antibody drug discovery and I am delighted to join the company at this exciting time to help maximise the potential of the technology and progress compounds into clinical development."

About F-star  

F-star is a clinical-stage company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. F-star's management team has significant experience in building numerous successful biotech companies. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. Through application of its powerful Modular Antibody Technology™ platform F-star aims to dominate the bispecific antibody space in immuno-oncology. F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. The Company has built a comprehensive IP estate around this core technology and related applications, with over 50 patents filed and 27 already granted. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim. Furthermore, F-star's lead clinical-stage programme (FS102) has provided valuable validation around key aspects of the core technology such as ease of manufacturing, favourable drug stability, pharmacokinetics and immunogenicity.

For more information visit

For further information, please contact:

John Haurum, CEO

Hume Brophy
Mary Clark, Eva Haas, Alexia Faure

SOURCE F-star Biotechnology
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Elanco Expands Parasiticide Portfolio in US with New Product for Heartworm Disease, Intestinal Parasites
2. Vtesse, Inc. Expands Scientific Advisory Board and Appoints New VP of Clinical Operations to Support Late-Stage Clinical Study of Lead Drug Candidate VTS-270
3. Schlafender Hase Inc. expands its presence in the Americas
4. Sorrento Expands its Executive Management Team with Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead its in-house Bioprocess and Manufacturing Operations
5. Ajinomoto Althea, Inc. Expands Manufacturing Capabilities to Antibody Drug Conjugate (ADC) Fill Finish and Bioconjugation
6. Eli Lilly and Company Expands New York City Research and Development Site
7. Stratice Healthcare Expands Executive Management Team With Health IT Industry Veterans
8. Vigilant Biosciences, Inc. Expands Leadership Team, Appoints James P. Mc Menamy as Vice President, Commercialization
9. Premier Cannabis Testing Lab Expands To Oregon
10. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Expands Disinfectant Effectiveness/Qualification Services in St. Louis, MO
11. Urgent Care Provider CityMD Expands Into New Jersey
Post Your Comments:
(Date:7/1/2020)... ... July 01, 2020 , ... Stratodesk today announced a ... available on NComputing devices. Thanks to fantastic new growth and stellar adoption of ... new partnership that will make the full Stratodesk NoTouch OS branded image available ...
(Date:6/28/2020)... ... June 26, 2020 , ... Mediaplanet is proud to announce ... healthcare providers, advocates, and scientists to spread awareness of chronic lung disease as ... conditions. , More than 35 million Americans live with a chronic ...
(Date:6/25/2020)... ... June 25, 2020 , ... R3 Medical Training announced ... place in August at several locations. The first course is August 6-7, 2020 in ... course is being offered as a Virtual Live Stream option. , The two day ...
Breaking Medicine Technology:
(Date:7/4/2020)... ... July 03, 2020 , ... , a comprehensive ... Best Memory Care Facilities in Charleston, South Carolina. The guide identifies 5 memory ... , According to the Alzheimer’s Association , 5.6 million people age 65 ...
(Date:7/2/2020)... YORK (PRWEB) , ... July 02, 2020 , ... ... New York plastic and cosmetic surgeons, with medical offices located in Staten Island, Huntington ... will be relocating to a beautifully designed medical suite at The Parlor NYC at ...
(Date:7/2/2020)... ... 02, 2020 , ... Allegheny Health Network (AHN) today announced that John S. ... effective immediately. Dr. Lee succeeds Robert White, MD, who announced his plans for ... the year to help support a seamless transition. , Dr. Lee joins AHN from ...
(Date:7/1/2020)... ... , ... Dexur’s analysis of Medicare claims of hospitals within a ... Hospital , and Sky Ridge Medical Center had the best value ... tracks a patient’s episode of care from the date of admission for 90 days ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... specializing in the clinical development of psychedelics and analogues, announces its core executive ... experience in natural product drug discovery, novel formulations, and as distinguished researchers within ...
Breaking Medicine News(10 mins):